Deals Of The Week: Shire/Pervasis, Takeda/URL, Amgen/KAI
By adding Pervasis’ endothelial cell technology to the expertise it added with last year’s buyout of Advanced BioHealing, Shire is hoping to build its Regenerative Medicine unit into another powerhouse division, like its Human Genetic Therapies unit.
You may also be interested in...
Specialty pharma says it will position ESRD candidate Vascugel for success, just as Shire is doing with Dermagraft, acquired in last year’s buyout of Advanced BioHealing.
In purchasing privately held URL for $800 million, Takeda acquires gout drug Colcrys, which it will market alongside Uloric.
Amgen will get KAI’s late-stage-ready asset for a small upfront price and gives itself a logical line extension to its chronic kidney disease drug Sensipar.